Bayer breaks ground on German cell and gene therapy centre1 SHARESPosted: 19 September 2025 | Dominic Tyer (European Pharmaceutical Review) |Once completed, the Berlin site will also be the new home for one of the company’s Bayer Co. Construction has begun for Bayer’s new Berlin Center for Gene and Cell Therapies (BC GCT), with the German pharma company planning to have it up and running by 2028. The project will focus on translational research in cell and gene therapy (CGT), but the Berlin facility also has the wider aim of creating a biotech ecosystem to help start-ups bring novel therapeutic approaches into clinical development. Prof. Heyo Kroemer, Chairman of the Executive Board of the Charité university hospital, said: “With gene and cell therapies, we are pushing the boundaries of what is medically possible. It will also house a Good Manufacturing Practice (GMP) certified CGT production facility to be run by the Berlin-based contract drug manufacturing organisation (CDMO) ProBioGen.